RE:RE:So essentially our CMO Kellum has been with us....Just Spectalating, but perhaps , in the missing video, Kellum may have elaborated on the fact (as Ronco believes), that under the right set of circumstances, PMX can be an effective therapeutic in the ongoing fight against Covid, and that the EAA might be an effective (some would argue critical) companion diagnostic for Covid patients in order rule out endotoxemia (which often leads to a deadly form of Sepsis). Ronco's recommendation is to apply
precision medicine techniques, and to zero in on "the
golden hour" to battle endotoxemia derived after the patient is admited for Covid (directly as a result of Covid-19 or as secondary infections acquired in teh ICU). He also acknowledges that a sizeable percentage of Covid-19 patients become Endotoxemic, and run the risk of developing a severe form of Sepsis.
Maybe, for some reason, Spectral doesn't want to overly excite the market with this kind of disclosure at this stage of the game ?
The public message (so far): Covid-19 continues to delay our Trials.
The Reality?: IMHO. Covid could
substantially increase Spectral's
revenues in the long term, in the form of (1) increased use of the
EAA in ICU's as a form of
triage tool to rule out endotoxemia (Ronco's strong recommendation), and (2) if a subset of those monitored patients experience an elevation in endotoxins, and
PMX might is a proven and
viable therapy to remove same, and (3) if some of those Sepsis patients go on to develop a form of kidney failure or
AKI, that there is a need for more (highly
portable and easy to use) CRRTS (e.g SAMI), and (4) that if they are setting up for HP why not use the same CRRT machine (i.e.. the only one on the market that does
both CRRT and HP? in a patented way and (5) that if the significant percentage of surviving Covid/Sepsis patients experience permanent or chronic kidney injury, that a high percentage may elect to
Home Dialysis (DIMI) in the future once/if approved by the FDA - in order to achieve
better outcomes, at a
lower cost, and greater
ease of use, with
less water systems/plumbing set-up, in the comfort of their own homes.
Anyway, I'm looking forward to some more information from Spectral about the potential for long term increases in revenue potential and or an increase in size of the addressable market as a result of Covid-19. It is sorely needed and long overdue, and materially important to all Spectral shareholders, IMO.
Oddly perhaps, I view Covid as a SIGNIFICANT NET POSITIVE for Spectral's future. Let's see how it is spun in the coming days and weeks.
MM
SouthernTierTom wrote: 17 out of 18 videos are publically available from the 39th Vicenza course in Italy. 3 of the 4 EDT involved videos are also publically available ( see the website under presentation )
Where is the "Keynote lecture" the all important #18 of 18 or in our spectral specific playlist #4 of 4?
Can we "selectively" share critical information and limit the dissemination of said "intel" to the owners of the company and the people paying the slary of the "keynote speaker"?
Do share, clearly it is part of the 10, 20 and 30 year plan of the firm ; - )
Dr. Kellum Invited to Participate on Additional Featured Panels
TORONTO, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT) and its wholly-owned subsidiary Dialco Medical Inc. (“Dialco”), are pleased to announce that Dr. John Kellum, the Company’s CMO, will be featured as the keynote lecturer at the virtual 39th Vicenza Course on Acute Kidney Injury (AKI) and Continuous Renal Replacement Therapy (CRRT) from Tuesday, October 26, 2021, to Friday, October 29, 2021. Dr. Kellum will discuss the importance of industry-academia collaboration in sepsis research:
Keynote Lecture: Industry and Academia: joining the forces in AKI and Sepsis
October 30, 2021, at 7:30 AM Eastern Time
Additionally, Dr. Kellum has been invited to participate in in the following featured panels:
Cappuccino with Claudio Ronco: CRRT Technology Update
Host: Dr. Claudio Ronco; Guest: Dr. John Kellum and SAMI
October 27, 2021, at 11:00 AM Eastern Time – Sponsored by Dialco Medical Inc.
Symposium: Endotoxic Shock: From Pathophysiology to Advanced Targeted Solutions
Moderator: Dr. Claudio Ronco; Speakers: Dr. John Kellum and Dr. Silvia De Rosa
October 27, 2021, at 12:15 PM Eastern Time – Sponsored by Estor S.p.A
Meet the Expert: Biomarkers (EAA) – Guided Initiation of PMX Hemoperfusion in Sepsis
Moderator: Dr. Claudio Ronco; Speaker: Dr. John Kellum
October 28, 2021, at 10:10 AM Eastern Time – Sponsored by Spectral Medical Inc.